Now the FDA has just issued two “Study May Proceed” letters to the clinical investigator and trial site research organization. The Southern California-based research team will commence two Phase 2 clinical trials, including two controversial therapies involving combinations with Zinc, Vitamin D3 and Vitamin C, the antimalarial drug first embraced by much of the research establishment and ivermectin.
The Phase 2 ivermectin study NCT04482686 involves the treatment of 300 COVID-19 patients with a combination of therapies or a placebo and standard of care. The study treatment duration is 10 days with follow up for 6 months. The study drug combination includes ivermectin, Doxycycline, and dietary supplements including Zinc, Vitamin D3 and Vitamin C.
Meanwhile, the hydroxychloroquine Phase 2 study NCT04459702 seeks to determine whether a dual or quadruple therapy (involving the antimalarial drug as well as Azithromycin and Ritonavir and Lopinavir) is more effective at treating COVID-19. The FDA approved study calls for 200 participants.
Accompanying video from TrialSite:
https://youtu.be/FDNGWW_YeEM
FDA greenlight for Ivermectin clinical trials
Good news: the completion dates moved up a lot. Now there's a chance that we still need it, by the time BorodyMectin(tm) is patented and gets into the stores.
Estimated Study Start Date : September 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : April 2021
IIRC, the original primary date was September 2020 and the final completion January 2023.
The name Southern California Research Institute is confusing. Sounds like a campus organization or think tank. The study is being done by a business.
[-] stereomatch | 1 points | Sep 21 2020 12:23:38
Now the FDA has just issued two “Study May Proceed” letters to the clinical investigator and trial site research organization. The Southern California-based research team will commence two Phase 2 clinical trials, including two controversial therapies involving combinations with Zinc, Vitamin D3 and Vitamin C, the antimalarial drug first embraced by much of the research establishment and ivermectin. The Phase 2 ivermectin study NCT04482686 involves the treatment of 300 COVID-19 patients with a combination of therapies or a placebo and standard of care. The study treatment duration is 10 days with follow up for 6 months. The study drug combination includes ivermectin, Doxycycline, and dietary supplements including Zinc, Vitamin D3 and Vitamin C. Meanwhile, the hydroxychloroquine Phase 2 study NCT04459702 seeks to determine whether a dual or quadruple therapy (involving the antimalarial drug as well as Azithromycin and Ritonavir and Lopinavir) is more effective at treating COVID-19. The FDA approved study calls for 200 participants.
Accompanying video from TrialSite:
https://youtu.be/FDNGWW_YeEM FDA greenlight for Ivermectin clinical trials
permalink
[-] TrumpLyftAlles | 1 points | Sep 21 2020 12:32:38
This is the Borody trial.
Good news: the completion dates moved up a lot. Now there's a chance that we still need it, by the time BorodyMectin(tm) is patented and gets into the stores.
Estimated Study Start Date : September 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : April 2021
IIRC, the original primary date was September 2020 and the final completion January 2023.
The name Southern California Research Institute is confusing. Sounds like a campus organization or think tank. The study is being done by a business.
permalink